Evidence map›Paper›PMID 41103533›Full record

ArticleOncology letters2025

Non-surgical breast-conserving treatment using Kochi oxydol-radiation therapy for unresectable carcinomas II for patients with stage 0 to IIIC breast cancer.

Akihiro Hori, Taiju Shimbo, Jun Ikenaga, Takaaki Itami, Mari Mukai, Kazuma Kobata, Takashi Ogawa, Ayaka Kihara, Mio Nakata, Yuuki Yoshino and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Akihiro HoriDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Taiju ShimboDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Jun IkenagaDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Takaaki ItamiDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Mari MukaiDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Kazuma KobataDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Takashi OgawaDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Ayaka KiharaDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Mio NakataDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Yuuki YoshinoDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Satoshi TakenoDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Kanabu NawaDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Hiroto YoshiokaDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Keiji NiheiDepartment of Radiation Oncology, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Hironori AkiyamaDepartment of Dental Radiology, Osaka Dental University, Hirakata, Osaka 570-8507, Japan.
Ken YoshidaDepartment of Radiology, Kansai Medical University Medical Center, Moriguti, Osaka 573-1121, Japan.
Kosei KimuraDepartment of Breast and Endocrine Surgery, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.
Mitsuhiko IwamotoDepartment of Breast and Endocrine Surgery, Osaka Medical and Pharmaceutical University, Takatuki, Osaka 569-8686, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kochi Oxydol-Radiation Therapy for Unresectable Carcinomas (KORTUC) is a novel radiosensitizing treatment developed in Japan that involves intratumoral injections of hydrogen peroxide (H

Indexed as

breast cancerhydrogen peroxide therapyKochi oxydol-radiation therapy for unresectable carcinomas-breast-conserving treatmentnon-surgical treatmentradiosensitizer

Identifiers

PMID41103533
PMCPMC12521886

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.